BRIMONIDINE TARTRATE/TIMOLOL MALEATE- brimonidine tartrate, timolol maleate solution/ drops États-Unis - anglais - NLM (National Library of Medicine)

brimonidine tartrate/timolol maleate- brimonidine tartrate, timolol maleate solution/ drops

apotex corp - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - brimonidine tartrate and timolol maleate ophthalmic solution 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop; the iop-lowering of brimonidine tartrate and timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [ see warnings and precautions   ( 5.1 , 5.3 ) ] . brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patie

XALAMOL 50/5 latanoprost 50 microgram/mL + timolol (as maleate) 5 mg/mL eye drops bottle Australie - anglais - Department of Health (Therapeutic Goods Administration)

xalamol 50/5 latanoprost 50 microgram/ml + timolol (as maleate) 5 mg/ml eye drops bottle

viatris pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); latanoprost, quantity: 50 microgram/ml - eye drops, solution - excipient ingredients: dibasic sodium phosphate; water for injections; monobasic sodium phosphate monohydrate; benzalkonium chloride; sodium chloride; hydrochloric acid; sodium hydroxide - reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. xalamol 50/5 should not be used to initiate therapy.

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION Canada - anglais - Health Canada

dorzolamide hydrochloride and timolol maleate ophthalmic solution

bausch & lomb inc - timolol (timolol maleate); dorzolamide (dorzolamide hydrochloride) - solution - 5mg; 20mg - timolol (timolol maleate) 5mg; dorzolamide (dorzolamide hydrochloride) 20mg - beta-adrenergic agents

GANFORT PF 0.3/5  bimatoprost 0.3 mg/mL and timolol (as maleate) 5.0 mg/mL eye drops Australie - anglais - Department of Health (Therapeutic Goods Administration)

ganfort pf 0.3/5 bimatoprost 0.3 mg/ml and timolol (as maleate) 5.0 mg/ml eye drops

abbvie pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml); bimatoprost, quantity: 300 microgram/ml - eye drops, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; hydrochloric acid; citric acid monohydrate; purified water; sodium chloride; sodium hydroxide - ganfort pf 0.3/5 eye drops are indicated for the reduction of intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.

GANFORT 0.3/5 bimatoprost 0.3 mg/mL & timolol (as maleate) 5.0 mg/mL eye drops bottle Australie - anglais - Department of Health (Therapeutic Goods Administration)

ganfort 0.3/5 bimatoprost 0.3 mg/ml & timolol (as maleate) 5.0 mg/ml eye drops bottle

abbvie pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml); bimatoprost, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; benzalkonium chloride; sodium hydroxide; purified water; citric acid monohydrate; hydrochloric acid; sodium chloride - ganfort eye drops are indicated for the reduction of intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.

TIMOLOL MALEATE solution États-Unis - anglais - NLM (National Library of Medicine)

timolol maleate solution

aton pharma, inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 2.5 mg in 1 ml

TIMOLOL MALEATE solution/ drops États-Unis - anglais - NLM (National Library of Medicine)

timolol maleate solution/ drops

remedyrepack inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 2.5 mg in 1 ml

APO-Latanoprost/Timolol 0.05/5 Eye drops latanoprost 50 ug/mL and timolol (as maleate) 5 mg/mL bottle Australie - anglais - Department of Health (Therapeutic Goods Administration)

apo-latanoprost/timolol 0.05/5 eye drops latanoprost 50 ug/ml and timolol (as maleate) 5 mg/ml bottle

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); latanoprost, quantity: 0.05 mg/ml - eye drops, solution - excipient ingredients: purified water; benzalkonium chloride; dibasic sodium phosphate dodecahydrate; sodium hydroxide; monobasic sodium phosphate dihydrate; hydrochloric acid; sodium chloride - reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. latanoprost/timolol (50 microgram/ml/5 mg/ml) eye drops should not be used to initiate therapy.

TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION, 0.25% solution/ drops
TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION, 0.5% so États-Unis - anglais - NLM (National Library of Medicine)

timolol maleate ophthalmic gel forming solution, 0.25% solution/ drops timolol maleate ophthalmic gel forming solution, 0.5% so

alembic pharmaceuticals inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic gel forming solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic gel forming solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings, obstructive pulmonary disease ]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings, cardiac failure ]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. timolol maleate ophthalmic gel forming solution 0.25% and 0.5% read this instructions for use that comes with timolol maleate ophthalmic gel forming solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timolol malea

TIMOLOL MALEATE solution États-Unis - anglais - NLM (National Library of Medicine)

timolol maleate solution

bausch & lomb incorporated - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - preservative-free timolol maleate ophthalmic solution in ocudose is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. preservative-free timolol maleate ophthalmic solution in ocudose may be used when a patient is sensitive to the preservative in timolol maleate ophthalmic solution, benzalkonium chloride, or when use of a preservative-free topical medication is advisable. preservative-free timolol maleate ophthalmic solution in ocudose is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.